Please assess the completion status of the following clinical trial:

Trial Title: Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects who have given their informed consent before any study-specific procedures~2. Histopathological diagnostic of NHL cell B CD 20 + B of different histologic subtypes:~3. High risk CD +20 Lymphoma having at least one of the following characteristics:~   * Less than a partial remission after two courses of treatment~  * Relapse after autologous peripheral blood stem cell (PBSCT)~  * Evidence of measurable disease (With CT and PET or PET / CT) three months after PBSCT~  * Hematopoietic precursors improper count in patients with relapsed or partial remission after two treatment lines that prevent the realization of a PBSCT.~  * Patients after first relapse in RP after two lines of treatment in whom the probability of freedom from progression per year is very low due to risk factors such as: first CR less than 12 months after PBSCT low SLP, etc..~4. Age between 18 and 65 years~5. ECOG between 0 to 1 (Appendix III).~6. Subjects who are HBgAG negative, anti-HBc positive and HBV DNA negative may be include in the study but must undergo HBV DNA monitoring~7. Adequate lung Function~8. Cardiac ejection greater than 40% as measured by scintigraphy or echocardiography.~9. Adequate renal and hepatic function defined by the following biochemical parameters~10. The disease status prior to transplantation had to be in place in accordance with the criteria of Revised Response Criteria for Malignant Lymphoma, Cheson 2007. CT and PET or PET / CT.~11. Availability of a histocompatible donor (9 to 10/10 loci) family or unrelated~12. Adults with ability to procreate must commit to use an effective method of birth control during the study treatment and at least 6 months.~Exclusion Criteria:~1. Refractory disease at the time of transplantation~2. Progressive disease at the time of transplantation.~3. ECOG≤2~4. Lymphoma associated with infection with human immunodeficiency virus (HIV).~5. Test positive for HIV.~6. Presence of anti-murine antibodies (HAMA) or (HACA).~7. Treatment with any marketed or experimental drug administered not in a period between 5 terminal half-lives of clearance of therapy or 4 weeks before enrollment~8. Participation in another interventional clinical trial.~9. Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months prior to start of therapy. This is generally required and may be excluded as applicable.~10. Hepatitis B positive serology~11. Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg.~12. Positive serology for hepatitis C (HC) defined as a positive test for HCAb.~13. Active liver or biliary disease (with exception of Gilbert's disease, cholelithiasis, metastases).~14. Other past or current malignancy.~15. Chronic infectious disease that requires ongoing treatment with systemic antibiotics, antifungal or antiviral drugs~16. History of cerebrovascular disease active in the last 6 months or event with significant symptoms or sequelae.~17. Clinically significant heart disease, such as unstable angina, acute myocardial infarction in the six months prior to inclusion, congestive heart failure (grades III-IV NYHA) and arrhythmia unless it is controlled by treatment, except for premature or disorders Mild driving.~18. Concurrent medical disorder, uncontrolled and important, such as kidney disease, liver, digestive, endocrine, pulmonary, neurological, brain, psychiatric, or which in the opinion of the investigator may represent a risk to the patient~19. Pregnancy or breastfeeding~20. Women of childbearing potential, including those whose last menstrual period was one year prior to screening.~21. Men unable or unwilling to use contraception~22. Patients with hypersensitivity to fludarabine, melphalan, thiotepa, tacrolimus, sirolimus and / or any excipients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ofatumumab (Type: EXPERIMENTAL): Ofatumumab as part of the reduced intensity conditioning regimen (RIC)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete